Rate My Professor Richard Troughton

Professor Richard Troughton is a Professor in Medicine in the Department of Medicine at the University of Otago, Christchurch campus, within the Health Sciences Division. He holds the qualifications MB ChB from the University of Auckland (1992), PhD from the University of Otago, and FRACP (2000). As a clinical cardiologist at Christchurch Hospital, he has sub-specialty interests in heart failure and cardiac imaging. Since 2009, he has been the co-lead for clinical research at the Christchurch Heart Institute, a University of Otago research centre, and serves as co-director of clinical studies there. He is also involved in the Hauora Manawa / Community Heart Study. Troughton oversees multi-year projects such as the IMPERATIVE-HF study, started in 2014, which investigates NT-proBNP-guided management to reduce heart failure readmissions.

His research focuses on neurohormonal control of cardiovascular and renal function, heart failure, echocardiography, left ventricular diastolic function, novel monitoring devices for heart failure, and cardioendocrinology. He evaluates biomarkers for diagnosis and management of cardiovascular disease and participates in clinical trials for novel heart failure therapies. Key publications include 'Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations' (The Lancet, 2000), 'A 2-hour diagnostic protocol for possible cardiac chest pain in the emergency department: a randomized controlled trial' (JAMA Internal Medicine, 2014), 'Natriuretic peptide-guided heart failure management' (European Heart Journal, 2014), and contributions to studies like the RELEVENT trial on left ventricular thrombus resolution. Troughton has received a Health Research Council grant of $730,000 over 36 months in 2017 for IMPERATIVE-HF, the Rowheath Trust Award and Carl Smith Medal in 2011, and Heart Foundation project grants in 2010. His 534 research works have garnered over 20,000 citations, influencing heart failure treatment and biomarker strategies internationally.